

Fuse Science, Inc.
Form 8-K
September 05, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported) September 5, 2012

FUSE SCIENCE, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada

(State or Other Jurisdiction)

of Incorporation)

000-22991
(Commission

87-0460247
(IRS Employer

File Number)

Identification No.)

6135 NW 167th Street, #E-21

33015

Miami Lakes, Florida

(Address of Principal Executive Offices) (Zip Code)

(305) 503-3873

(Registrant's telephone number, Including Area Code)

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On September 5, 2012, the Board of Directors of Fuse Science, Inc. (the “**Company**”) extended the expiration date of the Company’s presently outstanding Series B Warrants (which were originally issued in a February 2012 private offering) from September 9, 2012 to September 21, 2012 and lowered the current \$.13 exercise price of the Series B Warrants to \$.11. In addition, for each presently outstanding Series B Warrant exercised by a holder on or before September 21, 2012, the Company will extend the expiration date of one (1) additional presently outstanding unexercised Series B Warrant held by such holder (if any) to November 9, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FUSE SCIENCE, INC.

By: /s/ Brian Tuffin

Brian Tuffin, Chief Executive Officer and Acting Chief Financial Officer

Dated: September 5, 2012